N
PSTX

Natixis’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Natixis’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,700,000
Closed -$11.6M – 1359
2021
Q4 		$11.6M Buy
+1,700,000
New +$11.6M 0.04% 350

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Natixis's PSTX Position: Q1 2022 in Review

Natixis sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2022, closing a stake of 1,700,000 shares — an estimated $11.6M sold.

Natixis first reported a position in PSTX in Q4 2021 and held it in 1 quarter. The position peaked at $11.6M in Q4 2021. 64 funds tracked by Wall St. Rank hold PSTX as of Q1 2022.

  • Natixis reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Natixis sold 1,700,000 Poseida Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $11.6M.
  • Natixis first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Natixis's Poseida Therapeutics, Inc. Common Stock position peaked at $11.6M in Q4 2021.
  • 64 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Natixis's 13F filing for Q1 2022, filed 13 May 2022.